Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaMichael J. Keating, Hagop M. Kantarjian, Susan O’Brien et al.|Journal of Clinical Oncology|2005Cited by 951
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Catherine J. Wu, Vivian M. Liu et al.|Cancer Cell|2019Cited by 361
Non-Hodgkin’s LymphomasAndrew D. Zelenetz, Furhan Yunus, Ranjana H. Advani et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 329
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z. Rassenti, Thomas J. Kipps, Sonia Jain et al.|Blood|2008Cited by 320
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Michael J. Keating, Deborah A. Thomas et al.|Blood|2003Cited by 254